Revolution Medicines Q3 revenue reaches $198 million after RASONQUE launch
RVMD•Revolution Medicines reported $198 million in third-quarter net product revenue following the U.S. launch of RASONQUE, and a net loss of $407 million. It reiterated 2026 GAAP operating expense guidance of $2.1 billion to $2.2 billion.
1. Revenue and expenses
Revolution Medicines reported third-quarter net product revenue of $198 million, driven by the initial U.S. launch of RASONQUE for metastatic pancreatic cancer. The company posted a net loss of $407 million as research and development and commercial expenses rose, including launch-related spending and higher headcount.
2. European plans
The company said a positive CHMP opinion for daraxonrasib advances the path toward European Union approval. It is preparing for a potential European approval and commercial launch of RASONQUE, while a European Commission decision on the marketing application remains pending. Revolution Medicines reiterated its 2026 GAAP operating expense guidance of $2.1 billion to $2.2 billion.
